CTLA4 and cancer: Animal experiments related to Coprobacter have shown that this bacterium enhances the efficacy of immune checkpoint blockade (ICB) therapy, modulating CTLA‐4 or PD‐L1, pointing to a new direction for future cancer treatments [22, 31].